Recent Updates
Recently added Catalysts

Formulation A: OnabotulinumtoxinA

Phase 2

Glabellar Lines | Small molecule | Dermatology |AbbVie Inc.|Last Updated: Jun 27, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment92

FDA Designations

No designations recorded

Clinical trial landscape

Formulation A: OnabotulinumtoxinA · 1 trial · 1 indication

Phase 2 1
NCT05013424A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar LinesGlabellar Lines
COMPLETED92 Analytics
PHASE2COMPLETED
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Glabellar LinesUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Day 1 to Day 180

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment. The investigator assesses the relationship of each event to the use of the study. A serious adverse event (SAE) is an event that results in death, is life threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event, that based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/ treatment emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of the study drug.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Formulation A: OnabotulinumtoxinAEXPERIMENTALParticipants will receive one dose of OnabotA X administered as 5 injections to the corrugator and procerus muscles on Day 1.
Formulation B: OnabotulinumtoxinAEXPERIMENTALParticipants will receive one dose of OnabotA X administered as 5 injections to the corrugator and procerus muscles on Day 1.
Formulation C: OnabotulinumtoxinAEXPERIMENTALParticipants will receive one dose of OnabotA X administered as 5 injections to the corrugator and procerus muscles on Day 1.

Interventions

NameTypeDescription
Formulation A: OnabotulinumtoxinADRUGIntramuscular Injection
Formulation B: OnabotulinumtoxinADRUGIntramuscular Injection
Formulation C: OnabotulinumtoxinADRUGIntramuscular Injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Participant has sufficient visual acuity without the use of eyeglasses (contact lens use is acceptable) to accurately assess their facial lines. * Participant has severe GL at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale - G...

Countries:United States
Unlock Eligibility Criteria